165 related articles for article (PubMed ID: 19382534)
1. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab.
Keijsers RG; Verzijlbergen JF; van Diepen DM; van den Bosch JM; Grutters JC
Sarcoidosis Vasc Diffuse Lung Dis; 2008 Dec; 25(2):143-9. PubMed ID: 19382534
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis.
Keijsers RG; Verzijlbergen EJ; van den Bosch JM; Zanen P; van de Garde EM; Oyen WJ; Grutters JC
Sarcoidosis Vasc Diffuse Lung Dis; 2011 Oct; 28(2):123-9. PubMed ID: 22117503
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis.
Vorselaars AD; Crommelin HA; Deneer VH; Meek B; Claessen AM; Keijsers RG; van Moorsel CH; Grutters JC
Eur Respir J; 2015 Jul; 46(1):175-85. PubMed ID: 25929955
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of infliximab biosimilar Inflectra
Schimmelpennink MC; Vorselaars ADM; van Beek FT; Crommelin HA; Deneer VHM; Keijsers RGM; Veltkamp M
Respir Med; 2018 May; 138S():S7-S13. PubMed ID: 29496351
[TBL] [Abstract][Full Text] [Related]
5. ⁹⁹mTc-anti-TNF-α antibody for the imaging of disease activity in pulmonary sarcoidosis.
Vis R; Malviya G; Signore A; Grutters JC; Meek B; van de Garde EM; Keijsers RG
Eur Respir J; 2016 Apr; 47(4):1198-207. PubMed ID: 26797030
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effect of infliximab on refractory sarcoidosis.
Ørum M; Hilberg O; Krag S; Bendstrup E
Dan Med J; 2012 Dec; 59(12):A4535. PubMed ID: 23290282
[TBL] [Abstract][Full Text] [Related]
7. Earlobe sarcoidosis.
Vorselaars AD; Keijsers RG; Grutters JC
Sarcoidosis Vasc Diffuse Lung Dis; 2012 Mar; 29(1):55-7. PubMed ID: 23311125
[TBL] [Abstract][Full Text] [Related]
8. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis.
Vorselaars AD; Verwoerd A; van Moorsel CH; Keijsers RG; Rijkers GT; Grutters JC
Eur Respir J; 2014 Feb; 43(2):602-9. PubMed ID: 23988768
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis.
Keijsers RG; Verzijlbergen FJ; Oyen WJ; van den Bosch JM; Ruven HJ; van Velzen-Blad H; Grutters JC
Eur J Nucl Med Mol Imaging; 2009 Jul; 36(7):1131-7. PubMed ID: 19259660
[TBL] [Abstract][Full Text] [Related]
10. Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET.
Milman N; Graudal N; Loft A; Mortensen J; Larsen J; Baslund B
Clin Respir J; 2012 Oct; 6(4):238-47. PubMed ID: 22128762
[TBL] [Abstract][Full Text] [Related]
11. Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy.
Russell E; Luk F; Manocha S; Ho T; O'Connor C; Hussain H
Semin Arthritis Rheum; 2013 Aug; 43(1):119-24. PubMed ID: 23332903
[TBL] [Abstract][Full Text] [Related]
12. Correlation of spleen metabolism assessed by 18F-FDG PET with serum interleukin-2 receptor levels and other biomarkers in patients with untreated sarcoidosis.
Kalkanis A; Kalkanis D; Drougas D; Vavougios GD; Datseris I; Judson MA; Georgiou E
Nucl Med Commun; 2016 Mar; 37(3):273-7. PubMed ID: 26544095
[TBL] [Abstract][Full Text] [Related]
13. Responsiveness of FDG PET/CT to treatment of patients with active chronic sarcoidosis.
Sobic-Saranovic DP; Grozdic IT; Videnovic-Ivanov J; Vucinic-Mihailovic V; Artiko VM; Saranovic DZ; Pavlovic SV; Obradovic VB
Clin Nucl Med; 2013 Jul; 38(7):516-21. PubMed ID: 23486337
[TBL] [Abstract][Full Text] [Related]
14. ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy.
Vorselaars AD; van Moorsel CH; Zanen P; Ruven HJ; Claessen AM; van Velzen-Blad H; Grutters JC
Respir Med; 2015 Feb; 109(2):279-85. PubMed ID: 25496652
[TBL] [Abstract][Full Text] [Related]
15. Clinical Response to Tumor Necrosis Factor-α Inhibitor Therapy in the Management of Cardiac Sarcoidosis.
Churchill R; Sykora D; Castrichini M; Arment C; Myasoedova E; Elwazir M; Bois J; Young K; Rosenbaum A
Am J Cardiol; 2023 Oct; 205():20-27. PubMed ID: 37579656
[TBL] [Abstract][Full Text] [Related]
16. In vivo evaluation of TNF-alpha in the lungs of patients affected by sarcoidosis.
Galli F; Lanzolla T; Pietrangeli V; Malviya G; Ricci A; Bruno P; Ragni P; Scopinaro F; Mariotta S; Signore A
Biomed Res Int; 2015; 2015():401341. PubMed ID: 25866780
[TBL] [Abstract][Full Text] [Related]
17. Quantification of pulmonary disease activity in sarcoidosis measured with
Schimmelpennink MC; Vorselaars ADM; Veltkamp M; Keijsers RGM
EJNMMI Res; 2019 Jun; 9(1):54. PubMed ID: 31197630
[TBL] [Abstract][Full Text] [Related]
18. [Value of 18F-fluorodeoxyglucose-PET in the diagonosis and monitoring of pulmonary sarcoidosis: a case report].
Kaneko M; Tomioka H; Kaneda T; Kubot M; Tani S; Fujii H; Katsuyama E; Okazaki M
Nihon Kokyuki Gakkai Zasshi; 2008 Jun; 46(6):505-9. PubMed ID: 18593000
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study.
Elzinga EH; van der Laken CJ; Comans EF; Boellaard R; Hoekstra OS; Dijkmans BA; Lammertsma AA; Voskuyl AE
J Nucl Med; 2011 Jan; 52(1):77-80. PubMed ID: 21149486
[TBL] [Abstract][Full Text] [Related]
20. The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis.
Lee PI; Cheng G; Alavi A
J Nucl Cardiol; 2017 Feb; 24(1):19-28. PubMed ID: 27813028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
